Implantable Cardioverter Defibrillator Market Size, Revenue, Region & Country Share, Trends, Growth Analysis Till 2030
According to MRFR analysis, the global implantable cardioverter defibrillator market size is expected to register a CAGR of 5.96% during the forecast period. Implantable Cardioverter Defibrillator (ICD) is used to record the heart's activity and treat dangerous ventricular arrhythmias with an electrical shock or pulse to the heart. Factors such as the growing aging population, changing lifestyles such as smoking and alcohol consumption, and the increase in demand for cardiac implants are responsible for the increasing prevalence of cardiac arrhythmias globally. This is likely to fuel the growth of the ICD market during the forecast period. In addition to this, improving efficacy of ICDs for the treatment of cardiac diseases over a period will also fuel the market. According to the American Heart Association, approximately 1.5 million cases of myocardial infarction occur annually, and the incidence rate is approximately 600 cases per 100,000 people in the US. According to the American College of Cardiology Foundation, sudden cardiac arrest (SCA) is also one of the leading causes of death worldwide and is responsible for 250,000 to 450,000 deaths per year in the US. Also, coronary artery disease is a major risk factor for sudden cardiac arrest (SCA).
The global
implantable cardioverter defibrillator (ICD) market is currently dominated by
numerous market players. The key players are involved in new product launches
and strategic collaborations to strengthen their market positions. For
instance, in May 2019, the US Food and Drug Administration (FDA) has approved
Boston Scientific's Emblem S-ICD that is used in the treatment of
cardiovascular diseases. Through this approval, Boston Scientific focuses on
strengthening its position in the US ICD market. Medtronic is developing
Extravascular (EV) ICD system, an innovative subcutaneous implantable defibrillator ICD that is
designed to terminate arrhythmias, post-shock pacing to protect from sudden
cardiac arrest, and temporary back-up bradycardia pacing.
Segmentation
By
Type
- Regular
ICD: Holdsthe highest share in the market due to the increasing
occurrences and growing incidence rates of autoimmune diseases.
- Cardiac
Resynchronization Therapy Defibrillators (CRT-D): Holds the second-largest
share in the market and is expected to grow at a moderate rate during the
forecast period. The growth is mainly due to increasing cardiac arrests
among patients, R&D by major players, and strategic partnerships
- Subcutaneous-ICD
(S-ICD): Holds the third-largest share in the market and is expected to
grow at a steady rate in the market during the forecast period. New
product launches, manufacturing facility expansion in emerging countries
such as India, China, Brazil, and other emerging countries could drive the
market.
- Others:
Covers accessories and small component parts of implantable cardioverter
defibrillators. This segment holds the least share in the market.
By
Indication
- Myocardial
Ischemia: Myocardial Ischemia is the largest as well as the
fastest-growing segment by indication as ICDs are majorly used in the
treatment of myocardial ischemia. Moreover, the prevalence rate of sudden
cardiac arrests is rising. Myocardial ischemia is further segmented into
symptomatic and asymptomatic.
- Acute
Myocardial Infarction: It is the second-largest segment in the market, and
this condition is also commonly called a heart attack. Acute myocardial
infarction is a life-threatening condition that occurs when blood flow to
the heart muscle is abruptly cut off, causing tissue damage. It is the
second-largest segment in the market by indication.
- Electrolyte
Imbalance and Drug Toxicity: It is the third-largest and fastest-growing
segment in the market.
By
End User
- Hospitals
& Clinics: This is the largest and fastest-growing market segment and
is projected to grow well beyond the forecast period. Hospitals and
clinics are primary care centers for individuals afflicted with type-1
diabetes and are also cost-effective. Moreover, in countries with
government-funded healthcare and a high prevalence of type-1 diabetes,
hospitals and clinics are the main treatment centers, which drives the
growth of the segment.
- Ambulatory
Surgical Centers: A more specialized treatment option, a large number of
specialty centers have established across the US and are being opened in
developing nations such as India and China. This segment is growing due to
the increased number of individuals afflicted with the condition and the
higher returns on investment from specialty centers as compared to
hospitals and clinics.
- Others:
The ease of availability and delivery of diabetes medication has led to
patients opting for home treatment. The segment also covers old age homes
as the geriatric population is highly susceptible to type-1 diabetes. The
segment is expected to grow as awareness regarding the condition increases
along with the ease of treatment.
Regional
Analysis
The market
has been divided, by region, into the Americas, Europe, Asia-Pacific, and the
Middle East & Africa. The ICD market in the Americas has further been
branched into North America and Latin America, with the North American market
divided into the US and Canada. The ICDs market in the Americas is likely to
hold a major share owing to the increased patient pool. The European ICD market
has been sub-divided classified as Western Europe and Eastern Europe. The
Western European market has further been classified categorized as Germany,
France, the UK, Italy, Spain, and the rest of Western Europe. The ICD market in
Asia-Pacific has been segmented into Japan, China, India, South Korea,
Australia, and the rest of Asia-Pacific. The Asia-Pacific ICD market is
projected to be the fastest-growing due to the increasing incidences of acute
myocardial infarction and myocardial infraction, growing aging population, and
changing lifestyle (smoking and alcohol consumption) in the region. The ICD
market in the Middle East & Africa has been divided into the Middle East
and Africa.
Key
Players
- Abbott
Laboratories (US)
- BIOTRONIK
(Germany)
- Boston
Scientific Corporation (US)
- Medtronic
(Ireland)
- MicroPort
Scientific Corporation (China)
- Koninklijke
Philips N.V. (Netherlands)
- Nihon
Kohden Corporation (Japan)
- Progetti
Srl (Italy)
- Fukuda
Denshi Co., Ltd (Japan)
- Getinge
(Sweden)
- ZOLL
Medical Corporation (US)
About
Market Research Future:
At Market
Research Future (MRFR), we enable our customers to unravel the complexity of
various industries through our Cooked Research Report (CRR), Half-Cooked
Research Reports (HCRR), & Consulting Services. MRFR team have supreme
objective to provide the optimum quality market research and intelligence
services to our clients.
Contact
us:
Market
Research Future (part of Wantstats Research and Media Private Limited),
99 Hudson
Street, 5Th Floor,
New York,
New York 10013
United
States of America
+1 628 258
0071
Email: sales@marketresearchfuture.com
Comments
Post a Comment